PR Newswire·Mar 5, 2026, 4:30 PM ET

Azitra, Inc. Announces Cancellation of 2026 Special Meeting of Stockholders

Azitra, Inc. (NYSE American: AZTR) cancelled its special meeting of stockholders originally scheduled for February 6, 2026, which had been adjourned due to a lack of quorum until March 6, 2026.
The company is a clinical stage biopharmaceutical firm developing therapies for precision dermatology using a proprietary platform of engineered proteins & topical live biotherapeutic products.
Azitra's lead program, ATR-12, utilizes an engineered S. epidermidis strain to treat Netherton syndrome, a rare, chronic skin disease with no approved treatments, & includes a Phase 1b clinical trial in adult patients.
The additional advanced program, ATR-04, uses an engineered S. epidermidis strain to treat EGFR inhibitor-associated rash, impacting approximately 150,000 people in the U.S.
The FDA has granted Fast Track designation to the ATR-04 program, & Azitra holds an open IND for this indication.
The company's platform includes a microbial library of approximately 1,500 bacterial strains augmented by artificial intelligence & machine learning technology.
The press release includes standard forward-looking statements & lists various risks such as trial delays, regulatory uncertainties, funding needs, & competition.
Norman Staskey serves as Chief Financial Officer, & Tiberend Strategic Advisors, Inc. handles investor & media relations inquiries.